ISSN: 1859 - 2872
Serum interleukin-2 and tumor necrosis factor-alpha level in patients with hepatocellular carcinoma
Main Article Content
Keywords
Abstract
Summary
Objective: To evaluate the changes of serum interleukin-2 (IL-2) and tumor necrosis factor-alpha (TNF-α) level in patients with hepatocellular carcinoma (HCC) and the relationship with characteristics and stage of tumours. Subject and method: Prospective, cross-sectional descriptive study carried out on 86 patients with HCC in Digestive Department of 103 Military Hospital. Serum IL-2 and TNF-α concentration was determined by IMMULITE 1000’s enzyme-amplified chemiluminescence assay. Result: Serum IL-2 levels in patients with HCC was 355.7 ± 137.4U/mL, the decrease less than 391U/mL accounted for 62.8%. There was a significant relationship between serum IL-2 levels and tumour size, volume and Barcelona staging classification. The decrease in serum TNF-α level and its relationship was not determined in the study. Conclusion: There was a decreasing in serum IL-2 concentration in patients with HCC, the level of change correlated with tumour size and volume and Barcelona staging classification for HCC.
Keywords: Hepatocellular carcinoma, interleukin-2, TNF-α.
Article Details
References
2. Lê Văn Trường (2006) Nghiên cứu điều trị ung thư biểu mô tế bào gan kích thước trên 5cm bằng phương pháp tắc mạch hóa dầu chọn lọc. Luận án tiến sĩ Y học, Học viện Quân y.
3. Budhu A, Wang XW (2006) The role of cytokines in hepatocellular carcinoma. J Leukoc Biol (80): 1197-1213.
4. Cai L, Zhang Z, Zhou L et al (2008) Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients. Clin Immunol (129): 428-437.
5. Chen ZY, Wei W, Guo ZX et al (2014) Using multiple cytokines to predict hepatocellular carcinoma recurrence in two patient cohorts. British Journal of Cancer 110: 733–740.
6. Ji L, Gu J, Chen L et al (2017) Changes of Th1/Th2 cytokines in patients with primary hepatocellular carcinoma after ultrasound-guided ablation. Int J Clin Exp Pathol 10(8): 8715-8720.
7. Jemal A et al (2011) Global cancer statistics. CA Cancer J Clin 61(2): 69-90.
8. Palmieri G, Montella L, Milo M (2002) Ultra-low-dose interleukin-2 in unresectable hepatocellular carcinoma. Am J Clin Oncol (25): 224-226.
9. Zerki AN, El Deeb S, Bahnassy AA et al (2018) Role of relevant immune-modulators and cytokines in hepatocellular carcinoma and premalignant hepatic lesions. World J Gastroenterol 24(11): 1228-1238.
Article Sidebar
